Eriko Morino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eriko Morino has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Haruka Iwasaki
National Center for Global Health and Medicine
1 shared publication - Hideki Ebihara
Department of Virology I, National Institute of Infectious Diseases, Japan Institute for Health Security, Musashimurayama-shi, Japan
1 shared publication - Junko Terada-Hirashima
Center for Respiratory Medicine, National Center for Global Health and Medicine Hospital
1 shared publication - Masayuki Shimojima
Department of Virology 1, National Institute of Infectious Diseases
1 shared publication - Mugen Ujiie
Disease Control and Prevention Center, Japan Institute of Health Security, Tokyo, Japan
1 shared publication - Nobumasa Okumura
Department of Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan; Department of Infectious Diseases, Nagoya City University East Medical Center, Aichi, Japan
1 shared publication
Latest Publications
- Open Access
Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study
Monkeypox (mpox) is an acute exanthematous disease caused by the monkeypox virus (MPXV). Since May 2022, patients with mpox have been reported worldwide, mainly in Europe and the Americas. In Japan, LC16”KMB,” which is a smallpox vaccine derived from a dried cell culture, against mpox, has been approved. Although inoculation with a smallpox vaccine has been recommended to prevent MPXV infection, the immunogenicity of the smallpox vaccine against the MPXV is unclear, and information regarding postvaccination safety is scarce. We present the protocol for a single-arm open-label study to investigate the immunogenicity and safety of LC16”KMB” against the MPXV in healthy Japanese adults. The primary endpoint is the seroconversion rate of neutralizing antibodies against the MPXV on postvaccination day 28. The secondary endpoints are the seroconversion rates against the MPXV on postvaccination days 14 and 168; the seroconversion rates against the vaccinia virus on postvaccination days 14, 28, and 168; the incidence of mpox until day 168; and adverse and serious adverse events until postvaccination days 28 and 168. These results will pave the way for larger comparative studies using other smallpox vaccines to evaluate the test vaccine’s safety and efficacy in preventing mpox.
Open AccessEvaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study
Monkeypox (mpox) is an acute exanthematous disease caused by the monkeypox virus (MPXV). Since May 2022, patients with mpox have been reported worldwide, mainly in Europe and the Americas. In Japan, LC16”KMB,” which is a smallpox vaccine derived from a dried cell culture, against mpox, has been approved. Although inoculation with a smallpox vaccine has been recommended to prevent MPXV infection, the immunogenicity of the smallpox vaccine against the MPXV is unclear, and information regarding postvaccination safety is scarce. We present the protocol for a single-arm open-label study to investigate the immunogenicity and safety of LC16”KMB” against the MPXV in healthy Japanese adults. The primary endpoint is the seroconversion rate of neutralizing antibodies against the MPXV on postvaccination day 28. The secondary endpoints are the seroconversion rates against the MPXV on postvaccination days 14 and 168; the seroconversion rates against the vaccinia virus on postvaccination days 14, 28, and 168; the incidence of mpox until day 168; and adverse and serious adverse events until postvaccination days 28 and 168. These results will pave the way for larger comparative studies using other smallpox vaccines to evaluate the test vaccine’s safety and efficacy in preventing mpox.